• Email:
  • Password:
  • Remember Me
Lecture Hall Vascular Therapy | General
You have no lectures in your cart.
0 Lecture(s) Subtotal: $0.00

Indications risks and outcomes of lower extremity revascularization in patients with PVD

1 Year Subscription

Allan Hamdan
Allan Hamdan, MD
Director of Clinical Research
Division of Vascular Surgery
Beth Israel Deaconess Medical Center
System Requirements Method of Participation Disclosure Information
Lecture Transcription

Blank slide.


Good day! This is Dr. Allen D. Hamden, MD. I am a surgeon at the Beth Israel Deaconess Medical Center where I serve as the director for clinical research. Today’s lecture is on the indications, risks, and outcomes of lower extremity revascularization in patients with peripheral vascular disease.


The diagnosis of peripheral arterial disease ranges from 1-20% depending on the population you choose, risk factors, and the diagnostic techniques. The ratio of symptomatic to asymptomatic can be as high as 1:6. For every patient with claudication, there are another 3 who are estimated to have asymptomatic peripheral arterial disease. Basically, anyone with an ABI of 0.91 is considered to have peripheral arterial disease.


With the increasing age of the population in the United States, the prevalence of intermittent claudication is markedly increased. As you can see, as you get into the greater than 70 age group, the total number of patients with peripheral arterial disease is in the 4-5 million range.


This is just another depiction of as the population ages, the percentage who has peripheral arterial disease increases. This is also seen in both men and women.


The risk factors for atherosclerosis are included on the slide. As you can see, smoking is at the center of the problem as one of the most important things we can affect in our patients. On the left, age, diabetes,

obesity, and genetic conditions contribute to the development and progression of atherosclerosis. On the right, dyslipidemia including high triglycerides, high cholesterol, hypertension, the fairly rare hypercoagulable states, and then potentially hyperhomocysteinemia can also contribute to atherosclerosis.


Atherosclerosis can manifest at basically any arterial location; cerebrovascular manifestations would either be strokes or TIAs, in the coronary circulation, Q-wave MIs or non-Q-wave MIs or the unstable angina syndromes, renovascular hypertension or intestinal ischemia which is much less common than the other conditions listed above, and then in the lower extremities certainly claudication and potentially progressing to critical limb ischemia, rest pain, and gangrene.


This is a very simplistic depiction of the pathogenesis of acute ischemia. It basically starts with an atherosclerotic plaque which can be somewhat stable even if it is hemodynamically significant. Then the plaque can fissure or rupture and platelet thrombus forms on top of the plaque further increasing the luminal narrowing, and this can change into a worse or stabilized plaque or lead to in situ thrombosis of the vessel where there is complete occlusion acutely.


When you look at the overall group of patients with peripheral arterial disease, a very small percentage will have either severe limb ischemia, chronic or acute. Most patients will either have stable claudication or no symptoms at all.


This slide depicts 5-year outcomes of patients who were very closely monitored who had the starting diagnosis of just peripheral arterial disease and claudication. As you

can see, over 70% stayed stable, about 15% got worse, but only 7% needed bypass surgery and 4% needed major amputation. I generally tell patients who has claudication that the chance of them needing an amputation is about 1% per year, and that is roughly the same who will need some sort of revascularization 1-2% per year. Thus it is important to address the risk factors.


It is important to differentiate intermittent claudication, the vasculogenic claudication due to arterial circulation from some of the other conditions that could cause leg pain. The symptoms are generally described as an aching pain, sometimes heaviness or tightness or a cramp. It must be with exertion cramping and the large muscles at rest is not claudication. It has to occur in the large muscle groups; buttocks, calves, etc and not in the joints. This is sometimes difficult to differential in people with severe arthritis. It should be very reproducible from one day to the other. So, a patient who claudicates every time they walk up a certain hill in their neighborhood, it should happen every time they do it and not every other day or once a week. If patients describe very intermittent type symptoms, you have to question the diagnosis. Generally, the pain or cramping should resolve completely in about 5 minutes at most. I also like to ask them if they have to sit down for it to go away; that often indicates that they have spinal stenosis if they must sit down although they could have arterial circulation issues.


When trying to differentiate more severe conditions of lower extremity ischemia such as rest pain, this pain is different than that seen in claudication because it does not require any exertion for it to occur. Patients usually describe it as a pain although sometimes it is a numbness and it is seen over the metatarsal heads on the dorsal surface, worse with mild leg elevation. They identify it when they go to sleep since their legs are always elevated, sometimes they will tell you that they have to sleep in a chair with their legs hanging down. It often wakes them

up. They feel much better when they let their legs hang down, and in fact they will tell you that they often get up when they are sleeping, walk around a little bit, and it makes them feel better.


Certainly, if you see ulcerations or gangrene, it is a much easier diagnosis than trying to sort out rest pain in someone who has arthritis and who may have foot neuropathy of diabetes. Generally, the ulcerations are found distally. They are either at the end of the toes or over the bony prominences. It can present as a dry black eschar. It can either have intense pain in early stages or as the toe petrifies, there may be no pain related to toe specifically.


I have a particular interest in diabetes due to the fact that my institution is associated with the Josline Clinic and a high percentage of our patients have diabetes. It accelerates atherosclerosis several fold, increases the risk of coronary or ischemic events, there is a higher risk of stroke and the strokes are worse, and peripheral arterial disease often develops a decade earlier. Usually, you will see patients in the 50s or 60s who have diabetes presenting with lower extremity ischemia whereas in the nondiabetic population, which is usually the smokers or patients with high cholesterol, you will often see them in the late 60s or early 70s.


I would like to talk about some of the myths of patients with diabetes and vascular disease. They do not have intrinsic small vessel disease. They have a different pathobiology that will be described later but in and of itself, this idea that they have occlusion of their small vessels, which precludes healing of amputations or precludes successful bypass is wrong. There is also a feeling among people who do not routinely work with those with diabetes that when you try to revascularize them, it is not as successful as those in patients with diabetes. There is also a major issue with concerns about operating on patients with diabetes from the standpoint of cardiac risk and mortality from surgery. In fact if done properly, they can have the same or better mortality than in patients without diabetes.


Patients with diabetes who present with vascular disease, however, have an incredibly dismal 5-year survival, worse than some cancers. In other words, a patient who has diabetes who I do a bypass on, has a 5-year survival of about 50% and that is basically due their other comorbidities such as cardiac and cerebrovascular disease and that has not changed over the last decade.


To sort out this issue of the microcirculation, a number of investigators looked at amputation specimens and also extensive noninvasive testing and angiograms to once and for all prove that there is no such intrinsic disease or higher resistance of the small vessels, i.e., the arterials and the capillaries.


These are just studies if people are interested in looking at that essentially proved that there is no small vessel disease. My chairman, Dr. LoGerfo that you see on the third citing was influential in this education.

1. Conrad MC – Large and small artery occlusion in diabetics and nondiabetics with severe vascular disease. Circulation 1967; 36:83-91

2. Strandness DE Jr., Priest RE, Gibbons GE – Combined clinical pathological study of diabetic and nondiabetic peripheral arterial disease. Diabetes 1964; 13:366-72

3. Menzoian JO, Lamorte WW, Peniszyn CC, McBride KJ, Sidawy AN, LoGerfo FW, et al – Symptomatology and anatomic patterns of peripheral vascular disease: Differing impact of smoking and diabetes. Ann Vasc Surg 1989; 3:224-228

4. Goldenberg SG, Alex M, Joshi RA, Blumenthal HT – Nonatheromatous peripheral vascular disease of the lower extremity in diabetes mellitus. Diabetes 1959; 8:261-73


Now, saying that there is no small vessel disease is true but claim that patients with diabetes are the same as those without is wrong. There are major differences in the endothelial cell dysfunction even in those who do not have the diagnosis yet of diabetes but who will progress to diabetes. There is major thickening of the basement membranes of the capillaries. There is polyneuropathy which will be described later.


In essence, what is best described as the pathobiology of the foot is markedly altered in those with diabetes. Polyneuropathy accounts for the higher rate of ulceration at a given level of insufficiency. In other words, if you have two patients; one with and without diabetes who had 70% of their circulation intact, the patient with diabetes will be much more likely to develop an ulcer than the patient without for reasons related to the altered biology of the foot.


This is a description of the changes in the foot. There is a major loss of the pain receptors as well as the inflammatory response. This means that a patient could have a foreign body with pus in the plantar surface of the foot and not even amount an erythema or a white count. There is shunting of blood from the arteries to the vein leading to decreased tissue perfusion. There is thickening of the basement membrane as said on prior slides. There is a cavus deformity with increased pressure under the metatarsal heads leading to the mild perforance ulcer, the metatarsal head ulcer. There is marked decrease in sensation accounting for repetitive trauma that the patient with diabetes is not aware of, and then subsequently they have ulcer breakdown and then the toes are curled in the claw position. Certainly, the Charcot deformity is the outside scope of this presentation but that is another manifestation of the changes in the structure of the biology of the foot.


In the macrocirculation, the pathology of the stenotic or occlusive lesions is not different than in patients with and without diabetes. It is basically the same thing which is atherosclerosis.


However, the pattern of disease in macrocirculation is different. In general, patients who are smokers or have high cholesterol have disease in their iliac vessel and their proximal mid superficial femoral artery. Thus, patients with diabetes are often open down to their popliteal artery but then have tibial disease. They also very commonly have sparing of the dorsalis pedis artery making it a very good target for bypass.


Some general rules, both for those with diabetes and without. If they do not have a palpable foot pulse of both their dorsalis pedis and their posterior tibial locations unless the patient has significant swelling which complicates the physical exam, that is not normal. A hand-held Doppler is an incredibly sensitive test, so if you just hear a signal, that does not mean that the patient has adequate circulation. Patients who have just collateral vessels of the dorsalis pedis, may often have a loud Doppler signal. It is the character of the signal that is more important and this is better covered on my other lecture on the noninvasive evaluation of peripheral vascular disease.


Another thing that can fool clinicians is the location of an ulcer. For instance, the standard location for neuropathy and ulceration is over the metatarsal heads as described before. This can be in a patient with completely normal circulation and palpable pulses. However, just because it is in a neuropathic location, do not assume that it is only due to myopathy. There is a very high percentage of patients who have a combination of neuropathy and ischemia, thus you always have to evaluate for potential ischemia.


This is a standard location of a neuropathic ulcer. This is in a patient with osteomyelitis where the probe goes directly to bone, but in fact, this is a patient who also has significant arterial ischemia.


Another rule of thumb is an ulcer that is present for more than 2 months until you prove otherwise, has some ischemic component. Also, true gangrene of the toe as was seen on the other slide is almost always ischemic. It can be seen in repetitive trauma in patients with normal arterial circulation but that would be much less common.


It is important to have a treatment plan when you see any patient with vascular disease. If the patient has infection, that needs to be drained immediately regardless of whether they have ischemia or not. However, the flip side is in a patient who has the dry black eschars, especially healed eschars, do not start debriding them until you fix the circulation because all that will happen is you will remove the dead devitalized tissue and then it will desiccate beneath and further progress. It is very important to work with vascular surgeons who are familiar with revascularization either bypass or angioplasty, and the techniques of digital subtraction, angiogram is important, especially looking at the vessels below the knee in those with diabetes. Once you control the forefoot sepsis, you can reconstruct the vessels and then you need to plan the completion foot procedure. So, for instance, if the patient has an infected toe with plantar tracking, they may need an open ray with drainage, and then after control with antibiotics and the drainage procedure, they may need a bypass, and subsequently they may need closure of that ray or a transmetatarsal amputation.


We have had quite good success with the so called multidisciplinary approach which includes vascular surgeons, podiatrists, plastic surgeons, and the specialized nursing care unit. Just fixing the circulation is not enough. You have to prevent the ulcers by offloading pressure points and so it good to get your team involved even if it is not for a formal consultation on any cases that are not standard.


The revascularization whether it is a bypass or angioplasty should be performed before the final foot procedure, but that does not mean if they have sepsis and infection of the foot, that you wait until the circulation is restored. That is always treated first. We found over the course of thousands of foot amputations that if you try to do a foot amputation and it does not heal because of circulation issues, then you try to fix the circulation after the fact you end up losing a level, in other words, you may go from healing simple toe amputation to requiring the ray or transmetatarsal amputation, where from healing a transmetatarsal amputation to requiring a below-the-knee amputation. You try to do both these procedures during the same admission if possible.


What type of revascularization is chosen by the surgeon depends both on the lesion location and whether it is in arterial tree as well as what you have to use for conduit, i.e., available vein. So, it is important to establish inflow, inflow means, bringing blood from elsewhere to the groin or to the femoral artery. This can be done either by iliac stents, aortofemoral bypass or ileofemoral bypass, and in some situations even bringing blood from the axillary artery down to the groin.


Once you are sure that inflow is adequate either with surgery or angioplasty or knowing that from a physical exam or ultrasound study, then you have to assess for outflow or runoff issues. Outflow basically indicates any disease from the femoral artery down. Outflow issues can be treated by bypass from the groin down to the popliteal artery such as femoral popliteal bypass or to any of the tibial or foot vessels, which is much more commonly seen in the patients with diabetes.


So general rule, as stated above the nondiabetic patient has disease in the iliac vessels or the superficial femoral artery. Patients with diabetes often have disease below the popliteal artery so called trifurcation disease. Those patients may have a fairly strongly palpable popliteal but absolutely no foot pulses and very weak Doppler signals.


Regardless of the location of the bypass except when you are doing an aortobifemoral graft, the vein will perform better than any sort of prosthetic graft, Gortex, etc. Patency rates of both femoral to popliteal bypasses as well as the more distal tibial bypasses will be about 70-80% after 1 year and about 60% in 5 years. However, as I stated before, in all patients who need a bypass over the course of 5 years, at least 30% of them will be deceased and if they have diabetes in addition, almost half will be deceased, so that plays a role in choice.


When you are looking at the measures that vascular surgeons use for success, there is both patency of the bypass graft meaning that the graft is still functioning and then there is limb salvage which means that they have not had a major amputation, either a below-the-knee or above-the-knee amputation. Limb salvage includes patients who have transmetatarsal amputations that is considered safe. It always exceed patency; however, and that is basically that you may do a bypass healed foot wound, and then subsequently the graft will fail but the limb may stay on for a period of time even with an occluded graft.


This is a study that I will go over related to our institutions results in doing bypasses in patients with diabetes that detail over a thousand bypasses in patients with diabetes down to the dorsalis pedis artery.


A surgical approach to the bypass as you can see here, this is the dorsalis pedis artery exposed on the dorsum of the foot. We often can do a bypass so called short graft from the popliteal artery down to the dorsalis pedis. A vein is used exclusively. A flexible approach means the vein can be reversed. It can be taken off the common femoral artery. It can be taken off lower depending on the clinical situation. We can do the so-called in situ grafts where basically the vein remains in the saphenous bed except at the proximal distal anastomosis. The veins can be flipped around or the valves can be lysed. We often use angioscopy which is a scope placed inside the vein to evaluate for areas of stenosis and webbing, and it is very important to pay meticulous attention to closure of the wound, especially in the foot.


This is just to show that over 90% of the patients who have dorsalis pedis bypass as well as diabetes, and you can see the other standard risk factors.


In addition, as you can see on this slide, the majority of patients will undergo bypass for wound loss indications such as ulcers or gangrene


This slide is not crucial to memorize, but it just is important to show that it is ideal to work with vascular surgeons who have expertise in doing a number of different types of constructs using arm veins, lesser saphenous vein, etc.


Over here, you can see that the major complication rate is actually quite low. Only 1% of patients succumb to the surgery or mortality of less than 1%, but a number of them will have problems with heart attacks, renal failure, wound problems, etc, but overall it is a very safe procedure.


This details the patency rates. The difference between the primary and secondary patency just so you understand these terms. Primary is a graft is placed, nothing else is done to it and it stays patent. Secondary patency is a graft that is initially patent and then develops an areas say a stenosis in the mid graft and you fix that either with an angioplasty or patch repair of that vein, and then it subsequently stays patent for a longer period of time. Overall, you can see here that the patency rate at 5 years is over 60% as I detailed in prior study.


As I stated before, the limb salvage is always higher than the patency rate, and you can see here that almost 80% of patients who have a dorsalis pedis graft will still have their leg at 5 years.


So in conclusion, the dorsalis pedis bypass is very successful and very safe and leads to very high limb salvage rates, and has to be an armamentarium of any surgeon who is dealing with patients with diabetes.


So in general, because patients have different disease when they have diabetes, vein grafts are really the primary mode of treatment. The results of angioplasty using balloons and catheters for tibial vessels are sporadic but generally with poor long-term results. However, it may be indicated in certain patients especially if the goal is just to heal an ulcer or prepare for a foot procedure in someone who has an incredible surgical risk, but these are certainly the type of environments that you want to be practicing in if you have patients with diabetes where the surgeons or the interventionalists are very skilled at choosing which method is the proper one.


one other thing that I wanted to cover was this whole myth that patients with diabetes have an incredible mortality rate for any surgery, especially vascular unless they should just go directly to amputation. Diabetes is still listed as a major risk factor when you look at patients undergoing surgery.


We looked at over 6000 patients who underwent vascular surgery and you can see over 60% had diabetes.


As you can see here, a large percentage of patients have cardiac disease such as CHF, MI, or hypertension.


You can also see here that patients with diabetes present earlier than those without diabetes, but also will still have significant risk factors such as MI and CHF.


We looked at mortality rate and you can see here that patients with diabetes had even a lower mortality rate than those with no diabetes although they may have had higher rates of postoperative MI and CHF.


When we looked at our complicated statistical packages, we found that the only thing that really predicted higher death rates after bypass surgery was patients who were on dialysis and those patients who had congestive heart failure.


In fact, diabetes in this study which is over 6,000 patients, had an inverse effect on mortality. In other words, they actually had a lower rate of dying from the vascular procedures. Now, I am not claiming that it is good to have diabetes, but it certainly just opens up the options for these patients and it is not uncommon for me to see a patient who is a very good candidate from a standpoint of arterial reconstruction just because they had diabetes or told that a bypass will not work, and also that they have a high chance of dying from the surgery, and this is still occurring across the country today.


However, as I said before, almost half of these patients will be deceased 5 years after their vascular procedures. Patients without diabetes fare much better from a survival standpoint in the long run. It is probably due to the progression of coronary as well as cerebrovascular disease and also the higher risk of them being on the need for dialysis.


Some general conclusions; patients with diabetes do not have small vessel disease, bypass with their own veins mainly to the tibial vessels is a really durable procedure and allows for a number of foot procedures to be performed successfully, and less invasive modalities such as angioplasty and stenting are only suitable currently in special situations but it is certainly good to practice at a hospital or in network that has all these options.


Patients with diabetes can be expected to have a low morbidity and mortality rate from a number of different vascular surgery procedures. It really does not currently, in our minds, an independent risk factor for perioperative problems.


When seeing any patient with foot ischemia, they also have concurrent sepsis that needs to be dealt with first; that does not mean dried eschars, that means drainage of infection. Once that is done or while it is being done, it is important to evaluate as well as to treat the ischemia aggressively either with a bypass or angioplasty. We find that a multidisciplinary approach is the key. Once the revascularization procedure is intact, then a secondary foot procedure can be performed, and then most importantly is adjusting any risk factors to prolong the patient’s life such as cholesterol problems, smoking patterns, etc and to educate the patient and the family on proper foot care, proper shoes, and get them hooked up into a program where they are seeing both the vascular surgeon and their podiatrist regularly.


Many patients suffer from peripheral vascular disease and are treated by Podiatrists for ulcers, amputations, and pain. Dr. Hamdan in this lecture discusses the success, risks, benefits, etc of distal bypass revascularization surgery. He talks of truths and myths of diabetic patients and atherosclerosis disease, as well as the prevalence and manifestations of atherosclerosis.
Goals and Objectives
After participating in this activity, the viewer should be better able to:
1. Appreciate the prevalence and risk factors of PVD.
2. Identify the presentation and differentiate claudication from other causes of limb pain.
3. Know the myths and truths of diabetic patients with vascular disease.
4. Describe the role and methods of revascularization and its attendant morbidity and mortality.

Estimated time to complete this activity is 48 minutes.
Target Audience
Physicians, diabetes educators, and other health care professionals who treat patients with diabetes.
System Requirements
Indications risks and outcomes of lower extremity revascularization in patients with PVD
A Pentium-III class computer with a minimum of 256MB of system RAM is required to view Online Internet lectures. While a 56Kbps dial-up connection is supported, a Cable or DSL broadband Internet is strongly recommended for optimal video playback. You will need an up-to-date web browser such as Internet Explorer, Mozilla Firefox, or the AOL browser with Java and JavaScript enabled. Some lectures require the use of Internet Explorer to run and will not run with other browsers. Lectures may require the use of helper applications or plug-ins to access the materials. For example, most online lectures/presentations require either Adobe Flash Player or Windows Media Player (both free). To be able to print completion certificates Adobe Acrobat Reader must be installed.
Method of Participation
Indications risks and outcomes of lower extremity revascularization in patients with PVD
Complete the 4 steps to earn CE/CME credit:
  • Complete and submit the required pre-test
  • View Lecture
  • Complete and submit post-test and program evaluation. Credit will be issued with a passing score of 70% or better.
  • Click Print Certificate.
Disclosure Information
Indications risks and outcomes of lower extremity revascularization in patients with PVD
It is the policy of PRESENT e-Learning Systems and it's accreditors to insure balance, independence, objectivity and scientific rigor in all individually sponsored or jointly sponsored educational programs. All faculty participating in any PRESENT e-Learning Systems programs are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts.
Allan Hamdan, MD has nothing to disclose.
Privacy Policy
Indications risks and outcomes of lower extremity revascularization in patients with PVD
This web site will respect the confidentiality of the information that is transmitted on it in accordance with the provisions of this Agreement. The Web Site uses a random identifier, which is a session number attributed to the Registered User as he enters the site. This session number is expunged of the Web Site system as Registered User leaves. Please be advised that the Registered User's visit to the Web Site leaves a retrievable trace that allows the Web Site to gather raw data on the Registered User. Such technical retrieving system is necessary in order to secure the Web Site system.

This web site uses statistic and measurement systems which compile and process information such as IP numbers and number of visited pages. This information is processed in order to establish members' profiles and trends that may lead to, for example, market studies.

By registering to Web Site services, the Registered User agrees that his/her personal information may be archived in the members database of the Web Site and be used to transmit newsletters published by the Web Site and communications such as press releases or commercial information by the Host.

Information We Collect

In this section of our Privacy Policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors

Visitors to each of our Web sites can access the Web site's home page and browse some areas of the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you. On most of our Web sites, you must register with us to use the entire site.

Information We Collect When You Register

Customers registering for services on our Web sites are asked to provide us with identifying information, such as name, gender, contact information, and other personal information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion. You will also be given a choice about whether or not you want to receive newsletters and other information that we distribute from time to time. This PRESENT e-Learning Systems Web site will explain how personally identifiable information will be used and ask for your consent before collecting it.

Other Information

Discussion Boards: When you use a discussion board on one of our Web sites, you may post a message and your user name, which is available for all registered users to see. When you are posting publicly, any user of our Web site can see your message. You should not post any information you want or are required by law to keep private to a discussion board or other public forum on our Web sites.

My CV (Curriculum Vitae): On our web site, we offer an online data based profiling tool in which you supply information that is part of your curriculum vitae or professional resume. This tool stores the information that you provide on our servers. The information is accessible by other members and the public, and is designed to advertise you to the online community and allow other's to find you based on the information that you provide. We will always make it clear to you when information you provide to us through a tool will be saved.

Member Lookup: On our website, other members will be able to look you up and send you messages. If you opt not to be listed (blocked), no other members will be able to look you up.

In addition, we gather information about you that is automatically collected by our Web server, such as your IP address and domain name. We will use this information to personalize its offerings and presentations to you, facilitate your movements throughout our Web sites, provide personalized services, and to communicate with you individually.

Continuing Medical Education

When you register for a Continuing Medical Education ("CME") or a Continuing Education ("CE") activity through our web site, we collect certain personally identifiable information from you such as your name, email address and mailing address. We require that you provide the state in which you are licensed and your license number. In addition to personally identifiable information, we collect aggregated non-personally identifiable information about the activities undertaken by our users. We use the information that we collect through CME/CE activities in several ways:

(i) We are accredited by the Accreditation Council for Continuing Medical Education ("ACCME") to provide continuing medical education for physicians, through a sponsorship agreement with the Mount Sinai School of Medicine. As an ACCME accredited entity, we are required periodically to submit aggregated data about CME participants and the CME activities we certify. We also provide personally identifiable information to other accredited CME/CE providers who certify CME/CE activities posted on our Web sites, as required by the ACCME and other accrediting bodies. These reports may include personally identifiable information about you and credits issued to you, for the purpose of maintaining records that you can request from the accredited provider for up to six (6) years;

(ii) Commercial supporters of CME/CE activities on our Web site will receive only a data about CME/CE activities that are relevant to their interests and/or the courses they support;

(iii) Our Editorial and Customer Support Staff will have internal access to files containing personally identifiable information, including evaluation forms and aggregated CME /CE participant information. These files can be accessed in order to respond to your questions or comments. Our staff may also use personally identifiable information, including registration information and evaluation data, in assessing educational needs and planning marketing activities; and we may use the information we collect as otherwise permitted in this Privacy Policy.

Use of Cookies

Cookies are a technology we use to keep track of users as they move through our Web sites. Your browser allows us to place some information on your computer's hard drive that is associated with the computer you are using. We use cookies to personalize our Web sites and to track your usage across all of our Web sites. Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user, we may elect to associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web sites "remember" your user name and password and bypass the sign-in process on each visit to the site. Without cookies, this functionality would not be possible. Some of our business partners may use cookies on our site (for example, advertisers.) We have told them that we do not want them to use cookie information to track our users' activities once they leave our Web sites. However, because of the way advertisements are served on our Web sites, we do not have total control over how advertisers use cookies on our Web site. If you believe that one of our advertisers is placing an unwanted cookie on your hard drive, please contact privacy officer ( privacy@presentdiabetes.com ) to assist us in resolving the problem.

Uses We Make of Information

In this section of our Privacy Policy, we identify the ways we may use information about you that we have collected.

Aggregate Data

We collect data about visitors to our Web sites for product development and improvement activities. We also use it for market analysis. We may provide information from our Web sites in aggregate form, with identifying information removed, to third parties. For example, we may tell a health care partner what percentage of our registered users are of a particular medical specialty or have certain credentials. Any third party that receives our data must agree not to attempt to re-identify the people it belongs to. For example, we may provide information to a potential advertiser of a product that would appeal to a diabetes patient about what percentage of our users have diabetes. Depending on our agreement with the third parties, we may or may not charge for this information.

Marketing and Advertising

We may target our advertising or marketing depending on information we have about you. For example, a user that is a healthcare professional who treats diabetes may receive advertising for new diabetes therapies (although in neither case will the advertiser have access to any individually identifiable information about you). We may also personalize our Web site based on your interests. For example, you may see different articles in different places on our Web site based on information you have shared with us, or information we have gained by observing your previous behavior, or information we may have gained from your interactions with a third party that shares information with us. We use information for our own internal marketing, research, and related purposes. Third Parties In addition to aggregate information (discussed previously), we may share some kinds of personally identifiable information with third parties as described below.

Other Companies: We have strategic relationships with other companies who offer products and services on our Web sites. When you are interacting with those companies, different rules and privacy policies may apply. We do not control the collection or use of information you provide to these companies, but we do require that those companies clearly state their policies so you can decide whether to give them any information.

Our Employees and Consultants: We contract with other companies and individuals to help us provide services. For example, we may host some of our Web sites on another company's computers, hire technical consultants to maintain our Web-based tools, or work with companies to remove repetitive information from customer lists, analyze data, provide marketing assistance, and provide customer service. In addition, if you are a healthcare professional, we may validate your licensure status and other information against available databases that list licensed health care professionals. In order to perform their jobs, these other companies may have limited access to some of the personal information we maintain about our users. We require all such companies to comply with the terms of our Privacy Policy, to limit their access to any personal information to the minimum necessary to perform their obligations, and not to use the information they may access for purposes other than fulfilling their responsibilities to us. We use our best efforts to limit the use of other companies in areas where personally identifiable information may be involved.

Promotional Offers: Sometimes we send offers to selected groups of customers on behalf of other businesses. When we do this, we do not give that business your name and address. We provide a variety of mechanisms for you to tell us you do not want to receive such promotional offers. For example, we may provide an opt-in box for consumers to receive an email from another business, and we make clear that by opting in you are submitting your data to a third party.

Protection of Information

In this section of our Privacy Policy, we discuss the security measures we take to protect information that we have collected about you.

We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. We use security methods to determine the identity of its registered users, so that appropriate rights and restrictions can be enforced for that user. Reliable verification of user identity is called authentication. We use both passwords and usernames, as well as double opt-n verification, to authenticate users. Users are responsible for maintaining their own passwords.

Access to Information and Choices

In this section of our Privacy Policy, we tell you how to obtain and correct information we have about you, and how to choose what types of information you may share with us.

Correction of Information We Have About You

If you believe that registration information collected by our Web site(s) is in error, you may edit your personal profile any time that you like. You can directly edit most of your user profile on the Web site on which you initially registered. Information that you can not edit may only be changed by contacting Web Customer Support (see CONTACTS). Requests for deletion of your record may result in your removal from the registry, but we may keep certain demographic information about you for product improvement purposes. You may contact Web Customer Support and ask for the changes that you would like to make.

Our Employees

Our employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized employees are permitted to access personal information. Our employees with access to personally identifiable information are required to attend a confidentiality/privacy training class, and to sign a confidentiality agreement. All employees and contractors must abide by our Privacy Policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.
Copyright Statement
Indications risks and outcomes of lower extremity revascularization in patients with PVD
This website and its content is copyright of PRESENT eLearning Systems, LLC - © 2007- All rights reserved. Any redistribution or reproduction of part or all of the contents in any form is prohibited other than the following:

  1. You may print or download to a local hard disk extracts for your personal and non-commercial use only, and
  2. You may copy the content to individual third parties for their personal use, but only if you acknowledge the website as the source of the material

You may not, except with our express written permission, distribute or commercially exploit the content. Nor may you transmit it or store it in any other website or other form of electronic retrieval system.